![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia (S.M., E.G., S.V.T., P.D.P., V.G.); and Laboratory of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (S.I.)
Received November 6, 2006; accepted January 25, 2007.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
; De Luca and Coupar, 1996; Okada et al., 2002; Bodnar and Hadjimarkou, 2003). Three distinct types of opiate receptors have been identified at the molecular level: µ, 
, and 
(Waldhoer et al., 2004). These receptors exhibit differential involvement in eliciting the above-mentioned biologic processes. The action of opiates in inducing analgesia has tremendous therapeutic applications as evidenced from the current use of various opiate agonists as potent analgesics. There are several synthetic opiate agonists that include morphine, codeine, heroin, meperidine, and methadone. The remarkable ability of these agents to induce analgesia is also at least partly responsible for the abuse potential of such drugs. Available evidence indicates that the analgesic effects of opiates are mediated by µ and receptors (Waldhoer et al., 2004). The discovery of various receptors for exogenous opiates such as morphine led to the identification of endogenous opiates that function as physiologic ligands for these receptors. All endogenous opiates known to date are peptides. There are four classes of endogenous opioid peptides: enkephalins, endomorphins, dynorphins, and endorphins. These peptides are produced in vivo from different precursor proteins, which are found primarily in the brain and gastrointestinal tract.
Any classic neurotransmission process involving a specific neurotransmitter consists of four distinct components: synthesis of the neurotransmitter by the presynaptic neurons, release of the neurotransmitter at the synaptic cleft upon stimulation of the presynaptic neuron, interaction of the neurotransmitter with specific receptors on postsynaptic neurons or on the motor end-plate to initiate neurotransmission, and removal of the neurotransmitter from the synaptic cleft leading to the termination of neurotransmission. Different mechanisms participate in the removal of different neurotransmitters. For monoamines such as serotonin, dopamine, and norepinephrine, Na+/Cl–-coupled active transport systems are responsible for the removal process (Nelson, 1998). For acetylcholine, it is not a transporter but an enzyme (acetylcholinesterase) that mediates the clearance of the neurotransmitter by hydrolysis (Lane et al., 2004). What is the mechanism for the clearance of opioid peptides from the synapse? It is currently believed that peptidases are responsible for this process. This belief is based on identification of various peptidases that possess the ability to hydrolyze enkephalins. These peptidases include neutral endopeptidase, aminopeptidase N, angiotensin-converting enzyme, and dipeptidylaminopeptidase (Roques and Fournie-Zaluski, 1986; Roques, 2000). But, do these enzymes possess the ability to degrade opioid peptides other than enkephalins? Is the enzyme-dependent degradation of opioid peptides the only mechanism for the termination of opioidergic neurotransmission? Are there additional mechanisms for the clearance of opioid peptides from the synapse? Answers to these questions are sorely needed to fully exploit the opioidergic neurotransmission for therapeutic purposes.
Recently we made a serendipitous discovery that a Na+- and Cl–-coupled transport system mediates the entry of the synthetic opioid peptide deltorphin II into a human retinal pigment epithelial cell line (ARPE-19) (Hu et al., 2003). Such a transport system had not been described previously in the literature. The transport system interacts with a variety of opioid peptides containing 5 to 13 amino acids. We believe that the newly discovered transport system may have relevance to the biology of opioidergic neurotransmission. Because the transport system is energetically coupled to transmembrane gradients of Na+ and Cl–, such a system is ideal for effective clearance of opioid peptides from the synapse. To provide evidence in support of a role for the transport system in opioidergic neurotransmission, in the present study we tested whether SK-N-SH cells, a human neuronal cell line, express this transport system. These studies show that the neuronal cell line does indeed possess the Na+/Cl–-coupled transport activity for opioid peptides as monitored by the uptake of deltorphin II. More importantly, the activity of the transport system is modulated differentially by lysine and small nonopioid peptides. These findings have important implications in the biology and pharmacology of opioid peptides.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Culture of SK-N-SH Cells. SK-N-SH cells were cultured in Dulbecco's modified Eagle's medium, containing 1% nonessential amino acids, 1 mM pyruvate, 0.15% sodium bicarbonate, 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Uptake Measurements. Cells were seeded in 24-well culture plates at an initial density of 0.1 x 106 cells/well and cultured for 4 days. The culture medium was replaced with fresh medium on the 2nd day and uptake measurements were carried out on fourth day. To initiate uptake, the culture medium was aspirated out, and uptake buffer containing [3H]deltorphin II (25 nM; 
0.25µ Ci/assay) was added to the cells. Uptake was allowed to proceed for different time periods at 37°C, after which the uptake was terminated by the removal of the medium and washing of the cells with ice-cold uptake buffer. The cells were then dissolved in 1% SDS/0.2 M NaOH and radioactivity associated with the cells was measured. Most studies were done with a 30-min incubation period as uptake was found to be linear at least up to 30 min. The uptake buffer in most experiments was 25 mM HEPES/Tris (pH 7.5), containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, and 5 mM glucose. When the influence of Na+ on the uptake process was studied, the concentration of NaCl was adjusted by replacing NaCl with N-methyl-D-glucamine (NMDG) chloride iso-osmotically. When the influence of Cl– on the uptake process was studied, the uptake buffer was modified by replacing KCl and CaCl2 with equimolar concentrations of respective gluconate salts, and the concentration of NaCl was adjusted by replacing NaCl with sodium gluconate iso-osmotically.
Kinetic Analyses. Saturation kinetics was analyzed by fitting the data from uptake versus concentration experiments to the Michaelis-Menten equation, describing a single saturable transport system. The diffusional component was negligible (<5% total uptake). The Michaelis constant (Kt), the concentration of deltorphin II necessary for half-maximal uptake, was calculated by nonlinear regression analysis and then confirmed by linear regression using the Eadie-Hofstee equation. Na+- and Cl–-activation kinetics were analyzed by fitting the data to the Hill equation and the Hill coefficients for Na+ and Cl– (h, the number of Na+ or Cl– ions involved in the activation process) and the K0.5 values (the concentration of Na+ and Cl– necessary for half-maximal activation) were first calculated by nonlinear regression analysis and confirmed by linear regression.
Conformational Analysis. The most probable conformations of Tyr-Pro and Tyr-Leu (in vacuo, 25°C) were deduced by 20,000-step Monte Carlo conformational search using a Merck molecular force field. MacroModel software (version 8.6; Schrödinger LLC, San Diego, CA) was used for this purpose.
Data Analyses. Uptake measurements were made at least three times with independent cell cultures, and each experiment was done in duplicate or triplicate. Results from these replicates are given as means ± S.E. Statistical analysis was done by Student's t test, and a p value
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
Modulation of the Opioid Peptide Transport System by Small Nonopioid Peptides. Because the competition studies revealed that the uptake of deltorphin II was effectively inhibited by several opioid peptides consisting of five or more amino acids, we asked whether the transport system interacts with di- and tripeptides. To address this question, we tested the effects of 24 different dipeptides and 5 different tripeptides on the uptake of [3H]deltorphin II (25 nM) (Fig. 3). Peptides were present at 1 mM during uptake. About half of the dipeptides tested did not have any significant effect on [3H]deltorphin II uptake. These peptides were Gly-(N-methyl)glycine (Gly-Sar), Gly-Pro, Pro-Gly, Pro-Ala, Pro-Leu, Pro-Phe, Leu-Pro, Phe-Pro, and N-
-Ala-His (carnosine), suggesting that the transport system does not interact with these peptides. Two of the peptides, Lys-Asp and Tyr-Pro, caused significant inhibition of uptake (40%). On the other hand, some dipeptides stimulated the uptake of [3H]deltorphin II to a marked extent. These peptides were Ala-Gly, Ser-Tyr, Met-Ala, Leu-Gly, Ala-Met, Ser-Val, Met-Phe, Ser-Leu, His-Ala, Met-Glu, His-His, Ala-Ala, and Tyr-Leu. The stimulation varied over the range of 2.4- to 5.0-fold. Among the five tripeptides examined, all of them were found to have a marked stimulatory effect on [3H]deltorphin II uptake. These peptides were Gly-Gly-Ile, Gly-Gly-Phe, Gly-Gly-Gly, Tyr-Gly-Gly, and Glu-Gly-Phe. The stimulation varied over the range of 2.4- to 7.8-fold. The stimulation of [3H]deltorphin II uptake by these dipeptides and tripeptides suggests that the transport system possesses an allosteric modulatory site that binds to these stimulatory peptides to produce their effects.
|
It was noteworthy that none of the dipeptides containing proline stimulated the transport activity. In fact, some of them (e.g., Tyr-Pro) caused significant inhibition. Proline is unique in that it possesses an imino group rather than an amino group. When present in peptides, proline forms an N-substituted peptide bond and exerts substantial influence on the conformation of the peptides. Gly-Sar, which also has an N-substituted peptide bond, has no stimulatory effect. These data suggest that the presence of a regular peptide bond (–CO–NH–) may be obligatory for the stimulatory effect. Interestingly, Lys-Asp, which has a regular peptide bond, caused inhibition rather than stimulation, indicating that other conformational features play a critical role in determining the influence of these peptides. With those peptides that stimulated the transport activity, analysis of their size, charge, and lipophilicity and the corresponding magnitude of stimulation failed to show any relationship between these parameters and the influence on the transport activity. Among the dipeptides examined, Tyr-Pro showed maximal inhibition and Tyr-Leu showed maximal stimulation. Therefore, we deduced the conformation of these two dipeptides for comparison (Fig. 4).
|
|
|
|
|
Modulation of the Opioid Peptide Transport System by Free Amino Acids. The data in Fig. 6 showed that the uptake of [3H]deltorphin II was not influenced by small neutral amino acids. We then extended this study to all other amino acids to assess the influence of large aliphatic amino acids, aromatic amino acids, anionic amino acids, and cationic amino acids on the transport system (Fig. 9A). At a concentration of 1 mM, most of the amino acids tested had either no effect or minimal inhibitory or stimulatory effect on [3H]deltorphin II uptake. However, the cationic amino acid lysine had profound inhibitory effect, causing 90% inhibition. Because lysine was unique among the amino acids to show this inhibitory effect, we screened various structural analogs and derivatives of lysine for their influence on [3H]deltorphin II uptake (Table 1). These studies produced interesting results in terms of structural features necessary for the inhibitory effect. The ability of arginine and ornithine to inhibit the uptake process was much less than that of lysine, indicating that it was not just the cationic nature of the amino acids that was the basis for the effect. Lysine was inhibitory whereas lysinamide was not. This result would suggest the essential nature of the free carboxyl group of lysine for the inhibitory effect, but it does not seem to be the case because the methyl and ethyl esters of lysine were as potent as lysine as inhibitors of [3H]deltorphin II uptake. However, acetylation of the 
-amino group or the 
-amino group of lysine abolished the inhibitory effect almost completely. Polyamines such as diaminopentane and hexamethylenediamine and zwitterionic compounds such as 
-aminobutyric acid, -aminolevulinic acid, and 6-aminohexanoic acid showed little or no effect. Because lysine and its methyl and ethyl esters showed marked effects at a concentration of 1 mM, we performed dose-response studies for these three compounds (Fig. 9B). All three compounds had comparable potencies as inhibitors of [3H]deltorphin II uptake, with an IC50 value in the range of 150 to 180 µM. We also evaluated the influence of lysine on the kinetic parameters of the transport system (data not shown). The inhibition caused by lysine was primarily associated with a decrease in the maximal velocity (Vmax) with no significant change in substrate affinity (Kt).
|
|
We then evaluated the effect of lysine on deltorphin II uptake in the absence and presence of Gly-Gly-Ile (1 mM) to see whether lysine would have a similar inhibitory effect even in the presence of the stimulatory peptide. These studies showed that lysine (1 mM) caused 85% inhibition in the absence of Gly-Gly-Ile and 73% inhibition in the presence of Gly-Gly-Ile, indicating that the inhibitory effect of lysine is not altered by the presence of the stimulatory peptide.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). Because opioid peptides are found at high levels in the brain and are known to play an important role as modulators of pain perception, we thought that the transport system might be expressed in neurons. This led to the present report on the constitutive expression of the transport system in SK-N-SH cells. The characteristics of the transport system in SK-N-SH cells are comparable with those in ARPE-19 cells. The transport process is coupled to Na+ and Cl– and selectively interacts with opioid peptides. Dynorphin A1-13 is the most potent inhibitor of deltorphin II uptake via the transport system. The Na+/Cl–/opioid peptide stoichiometry is 2 or 3:1:1. The opioid peptide selectivity and order of their IC50 values to inhibit deltorphin II uptake in SK-N-SH cells are similar to those in ARPE-19 cells.
The Na+/Cl–-dependent opioid transport system identified in ARPE-19 cells (Hu et al., 2003) and in SK-N-SH cells (the present study) is distinct from any of the transport systems described previously for opioid peptides (Ganapathy and Miyauchi 2005). Four different transport systems that recognize opioid peptides have been identified in the blood-brain barrier (Banks and Kastin, 1990). These transport systems, known as peptide transport system (PTS)-1, PTS-2, PTS-3, and PTS-4, are Na+-independent and show no involvement of metabolic energy. Another transport system that is specific for endomorphins has also been described in the blood-brain barrier (Kastin et al., 2001; Somogyvari-Vigh et al., 2004). A distinct transport system specific for deltorphins, which shows partial Na+ dependence but with no evidence of concentrative uptake, has been described in brain microvessels (Fiori et al., 1997). None of these transport systems has been identified at the molecular level. Transport of opioid peptides has been demonstrated via some of the cloned transporters. This includes P-glycoprotein/ABCB1 (Sarkadi et al., 1994; Chen and Pollack 1998, 1999; Thompson et al., 2000; King et al., 2001; Oude Elferink and Zadina, 2001), organic anion transporting polypeptides (Gao et al., 2000; Cattori et al., 2001; Kullak-Ublick et al., 2001; Nozawa et al., 2003; Lee et al., 2005), and multidrug resistance-related protein MRP2/ABCC2 (Hoffmaster et al., 2004, 2005). None of these transport systems is Na+-dependent. There are two peptide transporters, PEPT1/SLC15A1 and PEPT2/SLC15A2, which handle dipeptides and tripeptides in mammalian tissues (Ganapathy and Miyauchi, 2003; Daniel and Kottra, 2004), but these transporters are H+-coupled and do not interact with opioid peptides. Thus, the Na+/Cl–-dependent opioid transport system identified in our laboratory is novel and is distinct from any of the previously described transport systems for opioid peptides.
The present studies have also unraveled an interesting, and pharmacologically and therapeutically relevant feature of this transport process. The transport system is modulated differentially by small nonopioid peptides and free amino acids. Specific dipeptides and tripeptides stimulate the transport system whereas lysine and its methyl and ethyl esters inhibit the transport system. The stimulation by small peptides is marked (2–8-fold), and significant stimulation is observed at micromolar concentrations of these peptides. Among the 24 dipeptides examined, proline-containing peptides were noticeably with no effect, whereas peptides containing hydrophobic amino acids (aliphatic and/or aromatic) are the ones with marked stimulatory effect. The same seems to be the case with tripeptides even though proline-containing tripeptides have not been tested. Because these dipeptides and tripeptides do not compete with deltorphin II for the uptake process, these peptides do not interact with the substrate-binding site. It is likely that the transport system possesses a modulatory site where these peptides bind and stimulate the transport activity. This is the first indication that it is possible to stimulate the uptake of opioid peptides into neurons using small molecules. These findings have pharmacologic implications because modulation of the transport system may mean modulation of opioidergic bioactivity. Stimulation of the opioid peptide transport system by nonopioid small peptides is expected to decrease the extracellular levels of opioid peptides, attenuating or terminating the activation of opiate receptors. Dipeptides and tripeptides are found in the brain (Teuscher et al., 2001). PEPT2, which transports dipeptides and tripeptides into cells, is expressed abundantly in the brain (Wang et al., 1998; Shen et al., 2004). Variations in the expression and activity of this transporter may lead to changes in the extracellular concentrations of specific small peptides which may function as the stimulators of the opioid peptide transport system. These findings have pharmacologic and therapeutic significance. It may be possible to design and develop small molecules with specific and potent stimulatory activity on the opioid peptide transport system. Such small molecules may be used as therapeutic agents to modulate opioidergic activity in vivo. Opioid peptides are found at high levels in the brain and in the gastrointestinal tract (Sundler et al., 1987), suggesting an important role for these peptides in these tissues. Because pharmacologic activation of the transport system is expected to decrease the bioactivity of endogenous opioid peptides, such therapeutic agents may be beneficial in the management of opiate addiction. In the gut, opioids promote constipation as evident from the therapeutic efficacy of opiate agonists (e.g., loperamide) as antidiarrheal agents. Therapeutic activation of the opioid peptide transport system may be useful to reduce the activity of endogenous opioid peptides and hence in the management of constipation.
The inhibition of the opioid peptide transport system by lysine may also have therapeutic relevance. Enhancement of the bioactivity of endogenous opioid peptides by interfering with the clearance of extracellular opioid peptides via inhibition of the transport system has potential in the management of pain. In the gut, lysine and similar small molecules that inhibit the transport system may have therapeutic use in the control of diarrhea. Therapeutic use of this naturally occurring amino acid to enhance opioidergic bioactivity will produce "physiologic" effects in terms of blunting the pain perception and preventing diarrhea. The main advantage of this approach is that the effects of lysine would be entirely due to potentiation of the actions of endogenous opioid peptides. These effects would involve only those opiate receptors that are tonically stimulated by endogenous opiates. On the contrary, exogenous opiate agonists are expected to stimulate all opiate receptors irrespective of the magnitude and duration of the interaction of these receptors with endogenous opioid peptides. Indiscriminate activation of opiate receptors may underlie the unwanted side effects such as drug dependence and withdrawal. A recent study by Smriga and Torii (2003) found lysine to be therapeutically useful as a partial serotonin receptor 4 antagonist. This study suggested that nutritional supplementation with lysine may be beneficial in the management of stress-induced anxiety and serotoninmediated diarrhea-prone intestinal dysfunctions. Our data suggest that lysine-induced enhancement of opioidergic neurotransmission in the enteric nervous system may also play a role in this phenomenon.
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: NMDG, N-methyl-D-glucamine; Sar, sarcosine (N-methylglycine); PEPT, peptide transporter; PTS, peptide transport system.
Address correspondence to: Dr. Vadivel Ganapathy, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912. E-mail: vganapat{at}mail.mcg.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, and Walker JM (1984) Endogenous opioids: biology and function. Annu Rev Neurosci 7: 223–255.[CrossRef][Medline]
Banks WA and Kastin AJ (1990) Peptide transport systems for opiates across the blood-brain barrier. Am J Physiol 259: E1–E10.
Bodnar RJ and Hadjimarkou MM (2003) Endogenous opiates and behavior: 2002. Peptides 24: 1241–1302.[CrossRef][Medline]
Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, and Hagenbuch B (2001) Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflueg Arch Eur J Physiol 443: 188–195.[CrossRef][Medline]
Chen C and Pollack GM (1998) Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287: 545–552.
Chen C and Pollack GM (1999) Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm Res (NY) 16: 296–301.
Daniel H and Kottra G (2004) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflueg Arch Eur J Physiol 447: 610–618.[CrossRef][Medline]
De Luca A and Coupar IM (1996) Insights into opioid action in the intestinal tract. Pharmacol Ther 69: 103–115.[CrossRef][Medline]
Fiori A, Cardelli P, Negri L, Savi MR, Strom R, and Erspamer V (1997) Deltorphin transport across the blood-brain barrier. Proc Natl Acad Sci USA 94: 9469–9474.
Ganapathy V and Miyauchi S (2003) Peptide transporters: physiological function and potential for use as a drug delivery system. Am Pharm Rev 6: 14–18.
Ganapathy V and Miyauchi S (2005) Transport systems for opioid peptides in mammalian tissues. AAPS J 7: E852–E856.[CrossRef][Medline]
Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, and Meier PJ (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294: 73–79.
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2004) Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 311: 1203–1210.[CrossRef][Medline]
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2005) Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab Dispos 33: 287–293.
Hu H, Miyauchi S, Bridges CC, Smith SB, and Ganapathy V (2003) Identification of a novel Na+- and Cl– system for endogenous opioid peptides in retinal pigment epithelium and induction of the transport system by HIV-1 Tat. Biochem J 375: 17–22.[CrossRef][Medline]
King M, Su W, Chang A, Zuckerman A, and Pasternak GW (2001) Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 4: 268–274.[CrossRef][Medline]
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with 3 other OATPs of human liver. Gastroenterology 120: 525–533.[CrossRef][Medline]
Lane RM, Kivipelto M, and Greig NH (2004) Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27: 141–149.[CrossRef][Medline]
Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, and Kim RB (2005) Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280: 9610–9617.
Nelson N (1998) The family of Na+/Cl– neurotransmitter transporters. J Neurochem 71: 1785–1803.[Medline]
Nozawa T, Tamai I, Sai Y, Nezu J, and Tsuji A (2003) Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol 55: 1013–1020.[CrossRef][Medline]
Okada Y, Tsuda Y, Bryant SD, and Lazarus LH (2002) Endomorphins and related opioid peptides. Vitam Horm 65: 257–279.[Medline]
Oude Elferink RPJ and Zadina J (2001) MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 22: 2015–2020.[CrossRef][Medline]
Roques BP (2000) Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 21: 475–483.[CrossRef][Medline]
Roques BP and Fournie-Zaluski MC (1986) Opioid peptides: molecular pharmacology, biosynthesis and analysis. NIDA Research Monograph Series 70: 128–154.
Sarkadi B, Muller M, Homolya L, Hollo Z, Seprodi J, Germann UA, Gottesman MM, Price EM, and Boucher RC (1994) Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 8: 766–770.[Abstract]
Shen H, Smith DE, Keep RF, and Brosius FC 3rd (2004) Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharmacol 1: 248–256.[CrossRef][Medline]
Smriga M and Torii K (2003) L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci USA 100: 15370–15375.
Somogyvari-Vigh A, Kastin AJ, Liao J, Zadina JE, and Pan W (2004) Endomorphins exit the brain by a saturable efflux system at the basolateral surface of cerebral endothelial cells. Exp Brain Res 156: 224–230.[CrossRef][Medline]
Sundler F, Bjartell A, Bottcher G, Ekblad E, and Hakanson R (1987) Localization of enkephalins and other endogenous opioids in the digestive tract. Gastroenterol Clin Biol 11: 14B–26B.[Medline]
Teuscher NS, Keep RF, and Smith DE (2001) PEPT2-mediated uptake of neuropeptides in rat choroid plexus. Pharm Res (NY) 18: 807–813.
Thompson SJ, Koszdin K, and Bernards CM (2000) Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92: 1392–1399.[Medline]
Waldhoer M, Bartlett SE, and Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73: 953–990.[CrossRef][Medline]
Wang H, Fei YJ, Ganapathy V, and Leibach FH (1998) Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain. Am J Physiol 275: C967–C975.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
10 µM and with Gly-Gly-Phe at concentrations 
) or presence (
) of Gly-Gly-Ile (1 mM). Data represent only Na+-dependent uptake, which was calculated by subtracting uptake measured in the absence of Na+. B, uptake of [3H]deltorphin II (25 nM) was measured for 30 min in the presence of increasing concentrations of Cl– (10–140 mM) but in the presence of a fixed concentration of Na+ (140 mM). The concentration of Cl– was varied by replacing NaCl with sodium gluconate iso-osmotically. Uptake measurements were made in the absence (
). Uptake measured in the absence of lysine or its esters was taken as the control (100%), and uptake measured in the presence of lysine or its esters is given as a percentage of this control value.